AJM onlineClinical research studyPrognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective
Section snippets
Study Setting
This prospective community surveillance study was conducted in Olmsted County, Minnesota and utilized the resources of the Rochester Epidemiology Project. The Rochester Epidemiology Project is a medical records linkage system that links and archives the medical records of nearly all persons living in the county.6 All medical diagnoses are maintained through an electronic index, and patients can be identified through their in- and outpatient contacts across the local medical providers.7 This
Results
A total of 1401 patients with incident myocardial infarction between November 2002 and December 2012 and stored samples for sST2 measurement were included in the study. The mean (SD) age was 67.3 (14.9) years, 61% were male, and 79% presented with non-ST-elevation myocardial infarction. The median sST2 value (ng/mL) was 49 (25th-75th percentiles, 33-104); 720 patients (51%) were considered to have elevated sST2, compared with published normal values.23
Higher values of sST2 were associated with
Discussion
To the best of our knowledge, we report herein on the largest community study to date, which evaluated, among incident myocardial infarction, the frequency of sST2 elevation, its clinical correlates, and its prognostic value. Our findings that, in a nonselected geographically defined cohort, sST2 is elevated in more than half of the patients presenting with an incident myocardial infarction, were unexpected. The substantial increase in the risk of death and heart failure with increasing levels
Conclusion
In this community cohort, sST2 is elevated in more than half of patients with incident myocardial infarction. Higher values of sST2 confer a markedly adverse prognosis characterized by a large excess risk of death and heart failure over a long period of follow-up. Measurement of sST2 should be considered as part of contemporary approaches to risk stratification after myocardial infarction.
Acknowledgment
We thank Susan Stotz, RN, Ellen Koepsell, RN, and Deborah Strain for their study support.
References (32)
History of the Rochester Epidemiology Project
Mayo Clin Proc
(1996)- et al.
Prognostic value of cardiac troponin T after myocardial infarction: a contemporary community experience
Mayo Clin Proc
(2012) - et al.
Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience
J Clin Epidemiol
(1996) - et al.
Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma—the Presage ST2 assay
Clin Chim Acta
(2009) - et al.
Association of ST2 levels with cardiac structure and function and mortality in outpatients
Am Heart J
(2010) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients
Am J Cardiol
(1967) - et al.
The biology of ST2: the International ST2 Consensus Panel
Am J Cardiol
(2015) - et al.
Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP
Am Heart J
(2011) - et al.
Heart disease and stroke statistics—2015 update: a report from the American Heart Association
Circulation
(2015)
Long-term trends in the incidence of heart failure after myocardial infarction
Circulation
Trends in incidence, severity, and outcome of hospitalized myocardial infarction
Circulation
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction
Circulation
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial
Clin Chem
Use of a medical records linkage system to enumerate a dynamic population over time: The Rochester Epidemiology Project
Am J Epidemiol
Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction
J Am Coll Cardiol
Cited by (68)
Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide
2023, Journal of Cardiovascular Development and DiseaseElevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
2023, Journal of Clinical MedicinePredictors of post-infarction left ventricular aneurysm
2023, Russian Journal of CardiologyBad players in AL amyloidosis in the current era of treatment
2023, Expert Review of Hematology
Funding: This work was supported by a grant from the National Heart, Lung, and Blood Institute (NHLBI; HL120957), Bethesda, MD and The Rochester Epidemiology Project (R01-AG034676). The funding sources played no role in the design, conduct, or reporting of this study.
Conflict of Interest: VLR reports grants from NHLBI, grant number HL 120957 during the conduct of the study. ASJ reports consulting from Beckman, Coulter, Siemens, Abbott, Roche, Alere, NeurogenomeX, Sphingotec, Single, and Novartis, outside the submitted work. All other authors report no conflicts of interest.
Authorship: All authors had access to the data and a role in writing the manuscript.